Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.11 HKD
−865.50 M HKD
5.99 B HKD
204.67 M
About SHENZHEN HEPALINK
Sector
CEO
Yu Shan
Headquarters
Shenzhen
Website
Founded
1998
ISIN
CNE100003YN2
FIGI
BBG00VNYVMK6
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the research, production and distribution of heparin sodium bulk drugs. It offers heparin sodium products including Food and Drug Administration (FDA) grade heparin sodium ingredients and ordinary grade heparin sodium ingredients. The company was founded by Li Tan, Li Li and Shan Yu on April 21, 1998 and is headquartered in Shenzhen, China.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 9989 is 4.10 HKD — it has decreased by −1.69% in the past 24 hours. Watch SHENZHEN HEPALINK PHARMACEUTICAL stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange SHENZHEN HEPALINK PHARMACEUTICAL stocks are traded under the ticker 9989.
9989 stock has fallen by −4.01% compared to the previous week, the month change is a −1.93% fall, over the last year SHENZHEN HEPALINK PHARMACEUTICAL has showed a 8.18% increase.
We've gathered analysts' opinions on SHENZHEN HEPALINK PHARMACEUTICAL future price: according to them, 9989 price has a max estimate of 7.85 HKD and a min estimate of 3.76 HKD. Watch 9989 chart and read a more detailed SHENZHEN HEPALINK PHARMACEUTICAL stock forecast: see what analysts think of SHENZHEN HEPALINK PHARMACEUTICAL and suggest that you do with its stocks.
9989 reached its all-time high on Aug 7, 2020 with the price of 19.48 HKD, and its all-time low was 2.39 HKD and was reached on Feb 5, 2024. View more price dynamics on 9989 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
9989 stock is 1.23% volatile and has beta coefficient of 1.14. Track SHENZHEN HEPALINK PHARMACEUTICAL stock price on the chart and check out the list of the most volatile stocks — is SHENZHEN HEPALINK PHARMACEUTICAL there?
Today SHENZHEN HEPALINK PHARMACEUTICAL has the market capitalization of 6.07 B, it has increased by 0.35% over the last week.
Yes, you can track SHENZHEN HEPALINK PHARMACEUTICAL financials in yearly and quarterly reports right on TradingView.
SHENZHEN HEPALINK PHARMACEUTICAL is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
9989 earnings for the last quarter are 0.09 HKD per share, whereas the estimation was 0.08 HKD resulting in a 13.03% surprise. The estimated earnings for the next quarter are 0.02 HKD per share. See more details about SHENZHEN HEPALINK PHARMACEUTICAL earnings.
SHENZHEN HEPALINK PHARMACEUTICAL revenue for the last quarter amounts to 1.35 B HKD, despite the estimated figure of 1.40 B HKD. In the next quarter, revenue is expected to reach 1.47 B HKD.
9989 net income for the last quarter is 126.69 M HKD, while the quarter before that showed 549.06 M HKD of net income which accounts for −76.93% change. Track more SHENZHEN HEPALINK PHARMACEUTICAL financial stats to get the full picture.
As of Dec 18, 2024, the company has 2.08 K employees. See our rating of the largest employees — is SHENZHEN HEPALINK PHARMACEUTICAL on this list?
Like other stocks, 9989 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SHENZHEN HEPALINK PHARMACEUTICAL stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SHENZHEN HEPALINK PHARMACEUTICAL technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SHENZHEN HEPALINK PHARMACEUTICAL stock shows the sell signal. See more of SHENZHEN HEPALINK PHARMACEUTICAL technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.